News

Ashley Holzworth-Nash, Pharm.D., head of product strategy and solutions at Evernorth, discusses her path from the pharmacy counter to shaping care models.

A survey with just over 400 employer respondents showed a declining percentage use one of three large pharmacy benefit managers (PBMs) to manage their drug benefits and coverage.

Novo Nordisk’s ziltivekimab lowers IL-6 heart inflammation but misses MACE reduction in ZEUS phase 3 CVD trial, with higher serious infections risk.

Raechele McMahan of Prescryptive Health says a cancer diagnosis at 17 and her son's type 1 diabetes made health care access personal before professional.

CMS has finalized a rule cutting federal Medicaid and CHIP funding for gender-affirming care for minors, effective Oct. 13, 2026.

Lower levels of the protein IQGAP2 were linked to more aggressive esophageal squamous cell carcinoma and worse survival.

Patrick Gleason, Pharm.D., of Prime Therapeutics was named a 2026 PBMI Innovator for his work on cost-effective formulary strategy and real-world evidence generation.

Online drug platforms are expanding quickly, but lower sticker prices do not always mean lower total costs for employees or better coordination of care.

Robyn S. Crosson, J.D., of Navitus Health Solutions, Elizabeth Mitchell of Purchaser Business Group on Health and Kathy W. Oubre, M.S., of the Pontchartrain Cancer Center, discussed PBM reform and transparency during an MHE webinar today.

Awiqli is the first once-weekly basal insulin for Type 2 diabetes. It has a list price of $99 a package and is also available for a $35 copay for eligible patients.

In this discussion, Hanna Gustafsson, Ph.D. and Elinor Sullivan, Ph.D., who are researchers from Oregon Health & Science University’s Center for Mental Health Innovation, explain the potential relationship between early childhood caregiving and ADHD.

Post-op oral dexamethasone after pediatric tonsillectomy reduces tonsillectomy pain and sharply lowers opioid prescribing and ED visits, a randomized trial finds.

The phase 3 trial will evaluate the efficacy of pemvidutide, a dual glucagon/GLP-1 receptor agonist, in metabolic dysfunction-associated steatohepatitis patients with moderate to advanced fibrosis, using an AI tool to standardize liver biopsy assessment.

David Chen, Pharm.D., of Kaiser Permanente discusses how PBM reform could speed biosimilar adoption and lower drug costs.

The real challenge for health plans isn’t simply deciding how to automate prior authorization but using this regulatory moment to build a far more durable cost-management strategy.

Phase 3 trials showed improvements in daytime wakefulness, cataplexy, and the disorder's full symptom range, including sleep paralysis and hallucinations.

New research in Menopause shows diabetic women face greater symptom burden during menopause transition, suggesting diabetes care should incorporate menopause symptom assessment and management.

Epic Research finds 2026 cholesterol guidelines and PREVENT-ASCVD expand statin eligibility to 54.6%, reshaping hyperlipidemia prevention and cardiovascular diseases risk.

Eric Levine, M.P.H., principal at Avalere Health, explains why a diagnosis alone won't exempt someone from the Medicaid work requirements that go into effect in 2027.

In June, the FDA's Vaccines and Related Biological Products Advisory Committee voted 9-0 in favor of Moderna’s mFlusiva, saying the benefits outweigh its risks for the prevention of influenza in adults older than 50.

Levine, a principal at Avalere Health, explains some of the details of Medicaid work requirements, including how activities of daily living may factor in and some of the leeway states have in how they are applied.

CMS's new interim rule sets an 80-hour monthly work requirement for many Medicaid enrollees but leaves states some latitude on setting medical exemptions and verification processes.

The finding is not novel, but it adds to the evidence base that atopic dermatitis makes people more susceptible to developing shingles.

A study by the American Diabetes Association also finds that 1.5 million diabetic Medicaid enrollees face new cost-sharing by 2029, potentially adding $1,000 in annual out-of-pocket costs in some states.

BeOne Medicines posts surging sales as Brukinsa leads blood cancer therapy growth, lifts 2026 outlook and adds new FDA approvals.

Melody Chang, RPh, BCOP, MBA, of the American Oncology Network, discusses building outpatient infrastructure for bispecific antibody and CAR-T therapy.

The researchers used efficiency frontier analysis, an alternative to quality-adjusted life years (QALYs), to rank adalimumab, secukinumab and bimekizumab, biologics used for hidradenitis suppurativa.

The Senate confirmed Erica Schwartz, M.D., J.D., M.P.H., 51-44, as CDC director, ending the agency's nearly year-long leadership vacancy.